Free tool
FAERS Monitor: Depo-Subq Provera 104
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021583 or its brand name (Depo-Subq Provera 104, Medroxyprogesterone Acetate). Reports on generic versions are filed under their own applications.
Reports
10,076
Serious
8,739
87% of reports
Hospitalization
1,213
Death reported
311
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- breast cancer female2,993
- breast cancer1,819
- meningioma844
- breast cancer metastatic434
- drug ineffective309
- off label use235
- oestrogen receptor assay positive215
- pain200
- ovarian cancer186
- nausea183
- progesterone receptor assay positive178
- fatigue167
- headache153
- vomiting151
- breast cancer in situ137
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,186 |
| 2005 | 855 |
| 2006 | 782 |
| 2007 | 197 |
| 2008 | 300 |
| 2009 | 481 |
| 2010 | 1,841 |
| 2011 | 504 |
| 2012 | 280 |
| 2013 | 89 |
| 2014 | 72 |
| 2015 | 123 |
| 2016 | 122 |
| 2017 | 113 |
| 2018 | 153 |
| 2019 | 217 |
| 2020 | 272 |
| 2021 | 212 |
| 2022 | 200 |
| 2023 | 240 |
| 2024 | 347 |
| 2025 | 791 |
| 2026 | 699 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,083 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| progesterone receptor assay positiveSignal | 178 | 491.7 | 418.2 | 70,168 |
| oestrogen receptor assay positiveSignal | 215 | 488.6 | 421.7 | 84,396 |
| breast cancer femaleSignal | 2,993 | 263.2 | 254.8 | 695,041 |
| breast cancer in situSignal | 137 | 252.1 | 211.4 | 30,351 |
| meningiomaSignal | 844 | 119.2 | 111.5 | 93,546 |
| breast cancer metastaticSignal | 434 | 87.9 | 80.0 | 35,721 |
| ovarian cancerSignal | 186 | 43.0 | 37.2 | 7,430 |
| breast cancerSignal | 1,819 | 41.5 | 39.8 | 70,821 |
| pain | 200 | 0.7 | 0.6 | 31 |
| vomiting | 151 | 0.7 | 0.6 | 25 |
| off label use | 235 | 0.6 | 0.5 | 84 |
| headache | 153 | 0.5 | 0.4 | 74 |
| drug ineffective | 309 | 0.5 | 0.4 | 175 |
| nausea | 183 | 0.5 | 0.4 | 105 |
| fatigue | 167 | 0.4 | 0.4 | 118 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.